Gene regulation by SMAR1: Role in cellular homeostasis and cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1815, Issue 1, 2011, Pages 1-12

  Malonia, Sunil Kumar ^a   Sinha, Surajit ^a   Lakshminarasimhan, Pavithra ^b   Singh, Kamini ^c   Jalota Badhwar, Archana ^d   Rampalli, Shravanti ^e   Kaul Ghanekar, Ruchika ^f   Chattopadhyay, Samit ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Piramal Enterprises Limited   (India)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f Bharati Vidyapeeth   (India)

Author keywords

Apoptosis; Cell cycle; Chromatin; NF B; Nuclear matrix; SMAR1

Indexed keywords

MATRIX ATTACHMENT REGION BINDING PROTEIN; NUCLEAR MATRIX PROTEIN; SCAFFOLD MATRIX ATTACHMENT REGION BINDING PROTEIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER GRADING; CARCINOGENESIS; CELL GROWTH; CELL HOMEOSTASIS; CELL NUCLEUS; CELL NUCLEUS MATRIX; CHROMATIN; CHROMOSOME 16Q; GENE CONTROL; GENE EXPRESSION; GENE LOCATION; GENE REPLICATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HOMEOSTASIS; HUMAN; MATRIX ATTACHMENT REGION; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, BCL-1; HOMEOSTASIS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 78650539222     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.08.003     Document Type: Review

References (153)

1. Berezney R., Coffey D.S. Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol 1977, 73:616-637.
2. Berezney R., Mortillaro M.J., Ma H., Wei X., Samarabandu J. The nuclear matrix: a structural milieu for genomic function. Int Rev Cytol 1995, 162A:1-65.
3. Samuel S.K., Minish T.M., Davie J.R. Altered nuclear matrix protein profiles in oncogene-transformed mouse fibroblasts exhibiting high metastatic potential. Cancer Res 1997, 57:147-151.
4. Nickerson J.A. Nuclear dreams: the malignant alteration of nuclear architecture. J Cell Biochem 1998, 70:172-180.
5. Coffey D.S. Nuclear matrix proteins as proteomic markers of preneoplastic and cancer lesions. Clin Cancer Res 2002, 8:3031-3033.
6. Zink D., Fischer A.H., Nickerson J.A. Nuclear structure in cancer cells. Nat Rev Cancer 2004, 4:677-687.
7. Smith H.C., Puvion E., Buchholtz L.A., Berezney R. Spatial distribution of DNA loop attachment and replicational sites in the nuclear matrix. J Cell Biol 1984, 99:1794-1802.
8. Bode J., Goetze S., Heng H., Krawetz S.A., Benham C. From DNA structure to gene expression: mediators of nuclear compartmentalization and dynamics. Chromosome Res 2003, 11:435-445.
9. Elcock L.S., Bridger J.M. Exploring the effects of a dysfunctional nuclear matrix. Biochem Soc Trans 2008, 36:1378-1383.
10. Zaidi S.K., Young D.W., Choi J.Y., Pratap J., Javed A., Montecino M., Stein J.L., van Wijnen A.J., Lian J.B., Stein G.S. The dynamic organization of gene-regulatory machinery in nuclear microenvironments. EMBO Rep 2005, 6:128-133.
11. Schneider R., Grosschedl R. Dynamics and interplay of nuclear architecture, genome organization, and gene expression. Genes Dev 2007, 21:3027-3043.
12. Zaidi S.K., Young D.W., Javed A., Pratap J., Montecino M., van Wijnen A., Lian J.B., Stein J.L., Stein G.S. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 2007, 7:454-463.
13. Galande S. Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer. Curr Cancer Drug Targets 2002, 2:157-190.
14. Chattopadhyay S., Pavithra L. MARs and MARBPs: key modulators of gene regulation and disease manifestation. Subcell Biochem 2007, 41:213-230.
15. Lever E., Sheer D. The role of nuclear organization in cancer. J Pathol 2010, 220:114-125.
16. Han H.J., Russo J., Kohwi Y., Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452:187-193.
17. Sparmann A., Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6:846-856.
18. Wotton S., Terry A., Kilbey A., Jenkins A., Herzyk P., Cameron E., Neil J.C. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 2008, 27:5856-5866.
19. Blyth K., Cameron E.R., Neil J.C. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005, 5:376-387.
20. Bae S.C., Lee Y.H. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 2006, 366:58-66.
21. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007, 7:899-910.
22. Oesterreich S. Scaffold attachment factors SAFB1 and SAFB2: innocent bystanders or critical players in breast tumorigenesis?. J Cell Biochem 2003, 90:653-661.
23. Jiang S., Meyer R., Kang K., Osborne C.K., Wong J., Oesterreich S. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol 2006, 20:311-320.
24. Khanuja P.S., Lehr J.E., Soule H.D., Gehani S.K., Noto A.C., Choudhury S., Chen R., Pienta K.J. Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 1993, 53:3394-3398.
25. Keesee S.K., Meneghini M.D., Szaro R.P., Wu Y.J. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci U S A 1994, 91:1913-1916.
26. Donat T.L., Sakr W., Lehr J.E., Pienta K.J. Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: intermediate biomarker candidates. Otolaryngol Head Neck Surg 1996, 114:387-393.
27. Luftner D., Possinger K. Nuclear matrix proteins as biomarkers for breast cancer. Expert Rev Mol Diagn 2002, 2:23-31.
28. Sjakste N., Sjakste T., Vikmanis U. Role of the nuclear matrix proteins in malignant transformation and cancer diagnosis. Exp Oncol 2004, 26:170-178.
29. Leman E.S., Getzenberg R.H. Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem 2008, 104:1988-1993.
30. Leman E.S., Getzenberg R.H. Nuclear matrix proteins as biomarkers in prostate cancer. J Cell Biochem 2002, 86:213-223.
31. Yanagisawa J., Ando J., Nakayama J., Kohwi Y., Kohwi-Shigematsu T. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in human breast carcinomas and not in normal and benign breast disease tissues. Cancer Res 1996, 56:457-462.
32. Chattopadhyay S., Kaul R., Charest A., Housman D., Chen J. SMAR1, a novel, alternatively spliced gene product, binds the scaffold/matrix-associated region at the T cell receptor beta locus. Genomics 2000, 68:93-96.
33. Birot A., Duret L., Bartholin L., Santalucia B., Tigaud I., Magaud J., Rouault J. Identification and molecular analysis of BANP. Gene 2000, 253:189-196.
34. Matsuda S., Rouault J., Magaud J., Berthet C. In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 2001, 497:67-72.
35. Chattopadhyay S., Whitehurst C.E., Chen J. A nuclear matrix attachment region upstream of the T cell receptor beta gene enhancer binds Cux/CDP and SATB1 and modulates enhancer-dependent reporter gene expression but not endogenous gene expression. J Biol Chem 1998, 273:29838-29846.
36. Chattopadhyay S., Whitehurst C.E., Schwenk F., Chen J. Biochemical and functional analyses of chromatin changes at the TCR-beta gene locus during CD4-CD8- to CD4+CD8+ thymocyte differentiation. J Immunol 1998, 160:1256-1267.
37. Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., Chattopadhyay S. Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. J Biol Chem 2005, 280:16019-16029.
38. Rampalli S., Pavithra L., Bhatt A., Kundu T.K., Chattopadhyay S. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol Cell Biol 2005, 25:8415-8429.
39. Kaul-Ghanekar R., Jalota A., Pavithra L., Tucker P., Chattopadhyay S. SMAR1 and Cux/CDP modulate chromatin and act as negative regulators of the TCRbeta enhancer (Ebeta). Nucleic Acids Res 2004, 32:4862-4875.
40. Abhiman S., Iyer L.M., Aravind L. BEN: a novel domain in chromatin factors and DNA viral proteins. Bioinformatics 2008, 24:458-461.
41. Suzuki H., Komiya A., Emi M., Kuramochi H., Shiraishi T., Yatani R., Shimazaki J. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosom Cancer 1996, 17:225-233.
42. Cleton-Jansen A.M., Callen D.F., Seshadri R., Goldup S., Mccallum B., Crawford J., Powell J.A., Settasatian C., van Beerendonk H., Moerland E.W., Smit V.T., Harris W.H., Millis R., Morgan N.V., Barnes D., Mathew C.G., Cornelisse C.J. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res 2001, 61:1171-1177.
43. Miller B.J., Wang D., Krahe R., Wright F.A. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 2003, 73:748-767.
44. Chou Y.H., Chung K.C., Jeng L.B., Chen T.C., Liaw Y.F. Frequent allelic loss on chromosomes 4q and 16q associated with human hepatocellular carcinoma in Taiwan. Cancer Lett 1998, 123:1-6.
45. Wang X., Gleich L., Pavelic Z.P., Li Y.Q., Gale N., Hunt S., Gluckman J.L., Stambrook P.J. Cervical metastases of head and neck squamous cell carcinoma correlate with loss of heterozygosity on chromosome 16q. Int J Oncol 1999, 14:557-561.
46. Mori Y., Matsunaga M., Abe T., Fukushige S., Miura K., Sunamura M., Shiiba K., Sato M., Nukiwa T., Horii A. Chromosome band 16q24 is frequently deleted in human gastric cancer. Br J Cancer 1999, 80:556-562.
47. Launonen V., Mannermaa A., Stenback F., Kosma V.M., Puistola U., Huusko P., Anttila M., Bloigu R., Saarikoski S., Kauppila A., Winqvist R. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet 2000, 122:49-54.
48. Vos C.B., ter Haar N.T., Rosenberg C., Peterse J.L., Cleton-Jansen A.M., Cornelisse C.J., van de Vijver M.J. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 1999, 81:1410-1418.
49. Gong G., DeVries S., Chew K.L., Cha I., Ljung B.M., Waldman F.M. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001, 7:2410-2414.
50. Powell J.A., Gardner A.E., Bais A.J., Hinze S.J., Baker E., Whitmore S., Crawford J., Kochetkova M., Spendlove H.E., Doggett N.A., Sutherland G.R., Callen D.F., Kremmidiotis G. Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics 2002, 80:303-310.
51. Singh K., Mogare D., Giridharagopalan R.O., Gogiraju R., Pande G., Chattopadhyay S. p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion. PLoS ONE 2007, 2:e660.
52. Kaul R., Mukherjee S., Ahmed F., Bhat M.K., Chhipa R., Galande S., Chattopadhyay S. Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice. Int J Cancer 2003, 103:606-615.
53. Jalota-Badhwar A., Kaul-Ghanekar R., Mogare D., Boppana R., Paknikar K.M., Chattopadhyay S. SMAR1-derived P44 peptide retains its tumor suppressor function through modulation of p53. J Biol Chem 2007, 282:9902-9913.
54. Wang S., El Deiry W.S. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 2006, 66:6982-6989.
55. Mahmoudi S., Henriksson S., Corcoran M., Mendez-Vidal C., Wiman K.G., Farnebo M. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 2009, 33:462-471.
56. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004, 4:793-805.
57. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
58. Pavithra L., Mukherjee S., Sreenath K., Kar S., Sakaguchi K., Roy S., Chattopadhyay S. SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription. J Mol Biol 2009, 388:691-702.
59. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
60. Thut C.J., Goodrich J.A., Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997, 11:1974-1986.
61. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
62. Meek D.W. The p53 response to DNA damage. DNA Repair (Amst) 2004, 3:1049-1056.
63. Koeppel M., van Heeringen S.J., Smeenk L., Navis A.C., Janssen-Megens E.M., Lohrum M. The novel p53 target gene IRF2BP2 participates in cell survival during the p53 stress response. Nucleic Acids Res 2009, 37:322-335.
64. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995, 10:775-778.
65. Gillett C., Smith P., Gregory W., Richards M., Millis R., Peters G., Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996, 69:92-99.
66. Yamamoto M., Tamakawa S., Yoshie M., Yaginuma Y., Ogawa K. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog 2006, 45:901-913.
67. Hui R., Finney G.L., Carroll J.S., Lee C.S., Musgrove E.A., Sutherland R.L. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002, 62:6916-6923.
68. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996, 68:67-108.
69. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998, 18:753-761.
70. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
71. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
72. Musgrove E.A. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006, 24:13-19.
73. Klein E.A., Assoian R.K. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008, 121:3853-3857.
74. Balmanno K., Cook S.J. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999, 18:3085-3097.
75. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400.
76. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999, 19:5785-5799.
77. Luo J.L., Maeda S., Hsu L.C., Yagita H., Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004, 6:297-305.
78. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
79. Cao Y., Bonizzi G., Seagroves T.N., Greten F.R., Johnson R., Schmidt E.V., Karin M. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001, 107:763-775.
80. Cao Y., Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003, 8:215-223.
81. Cicatiello L., Addeo R., Sasso A., Altucci L., Petrizzi V.B., Borgo R., Cancemi M., Caporali S., Caristi S., Scafoglio C., Teti D., Bresciani F., Perillo B., Weisz A. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004, 24:7260-7274.
82. Zhang Z.K., Davies K.P., Allen J., Zhu L., Pestell R.G., Zagzag D., Kalpana G.V. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 2002, 22:5975-5988.
83. Lu D., Wolfgang C.D., Hai T. Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 2006, 281:10473-10481.
84. D'Amico M., Wu K., Fu M., Rao M., Albanese C., Russell R.G., Lian H., Bregman D., White M.A., Pestell R.G. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements. Cancer Res 2004, 64:4122-4130.
85. Santra M.K., Wajapeyee N., Green M.R. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 2009, 459:722-725.
86. Meek D.W. Tumour suppression by p53: a role for the DNA damage response?. Nat Rev Cancer 2009, 9:714-723.
87. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9:402-412.
88. Sinha S., Malonia S.K., Mittal S.P., Singh K., Kadreppa S., Kamat R., Mukhopadhyaya R., Pal J.K., Chattopadhyay S. Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element. EMBO J 2010, 29:830-842.
89. Tanaka T., Ohkubo S., Tatsuno I., Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 2007, 130:638-650.
90. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., Campargue I., Naumovski L., Crook T., Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001, 8:781-794.
91. Bernardi R., Pandolfi P.P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007, 8:1006-1016.
92. Xu Z.X., Zhao R.X., Ding T., Tran T.T., Zhang W., Pandolfi P.P., Chang K.S. Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. J Biol Chem 2004, 279:1838-1844.
93. Yamada C., Ozaki T., Ando K., Suenaga Y., Inoue K., Ito Y., Okoshi R., Kageyama H., Kimura H., Miyazaki M., Nakagawara A. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem 2010, 285:16693-16703.
94. Yavuzer U., Smith G.C., Bliss T., Werner D., Jackson S.P. DNA end-independent activation of DNA-PK mediated via association with the DNA-binding protein C1D. Genes Dev 1998, 12:2188-2199.
95. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
96. Webster G.A., Perkins N.D. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 1999, 19:3485-3495.
97. Huang W.C., Ju T.K., Hung M.C., Chen C.C. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell 2007, 26:75-87.
98. Shen H.M., Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363.
99. Radhakrishnan S.K., Kamalakaran S. Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim Biophys Acta 2006, 1766:53-62.
100. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-897.
101. Shetty S., Graham B.A., Brown J.G., Hu X., Vegh-Yarema N., Harding G., Paul J.T., Gibson S.B. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005, 25:5404-5416.
102. Massague J., Blain S.W., Lo R.S. TGF beta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
103. Seton-Rogers S.E., Lu Y., Hines L.M., Koundinya M., LaBaer J., Muthuswamy S.K., Brugge J.S. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci U S A 2004, 101:1257-1262.
104. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
105. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
106. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520.
107. Feng X.H., Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005, 21:659-693.
108. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 2002, 21:3749-3759.
109. Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., Itoh S., Kawabata M., Heldin N.E., Heldin C.H., ten Dijke P. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997, 389:631-635.
110. Itoh S., ten Dijke P. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol 2007, 19:176-184.
111. Goldmann W.H., Ingber D.E. Intact vinculin protein is required for control of cell shape, cell mechanics, and rac-dependent lamellipodia formation. Biochem Biophys Res Commun 2002, 290:749-755.
112. Labat-Robert J. Fibronectin in malignancy. Semin Cancer Biol 2002, 12:187-195.
113. Bazzoni G. The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 2003, 15:525-530.
114. Zhu Q., Maitra U., Johnston D., Lozano M., Dudley J.P. The homeodomain protein CDP regulates mammary-specific gene transcription and tumorigenesis. Mol Cell Biol 2004, 24:4810-4823.
115. Michl P., Downward J. CUTL1: a key mediator of TGF beta-induced tumor invasion. Cell Cycle 2006, 5:132-134.
116. Erber A., Riemer D., Bovenschulte M., Weber K. Molecular phylogeny of metazoan intermediate filament proteins. J Mol Evol 1998, 47:751-762.
117. Brotherick I., Robson C.N., Browell D.A., Shenfine J., White M.D., Cunliffe W.J., Shenton B.K., Egan M., Webb L.A., Lunt L.G., Young J.R., Higgs M.J. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 1998, 32:301-308.
118. Willipinski-Stapelfeldt B., Riethdorf S., Assmann V., Woelfle U., Rau T., Sauter G., Heukeshoven J., Pantel K. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005, 11:8006-8014.
119. Ferrero M., Spyratos F., Le D., Desplaces V.A., Rouesse J. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. Cytometry 1990, 11:716-724.
120. Iwaya K., Ogawa H., Mukai Y., Iwamatsu A., Mukai K. Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. Cancer Sci 2003, 94:864-870.
121. Raul U., Sawant S., Dange P., Kalraiya R., Ingle A., Vaidya M. Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype. Int J Cancer 2004, 111:662-668.
122. Pavithra L., Singh S., Sreenath K., Chattopadhyay S. Tumor suppressor SMAR1 downregulates Cytokeratin 8 expression by displacing p53 from its cognate site. Int J Biochem Cell Biol 2009, 41:862-871.
123. Mukhopadhyay T., Roth J.A. Functional inactivation of p53 by antisense RNA induces invasive ability of lung carcinoma cells and downregulates cytokeratin synthesis. Anticancer Res 1996, 16:1683-1689.
124. Mukhopadhyay T., Roth J.A. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines. Anticancer Res 1996, 16:105-112.
125. Kaul-Ghanekar R., Singh S., Mamgain H., Jalota-Badhwar A., Paknikar K.M., Chattopadhyay S. Tumor suppressor protein SMAR1 modulates the roughness of cell surface: combined AFM and SEM study. BMC Cancer 2009, 9:350.
126. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947.
127. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107:241-246.
128. Greten F.R., Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004, 206:193-199.
129. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
130. Ho W.C., Dickson K.M., Barker P.A. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res 2005, 65:4273-4281.
131. Singh K., Sinha S., Malonia S.K., Bist P., Tergaonkar V., Chattopadhyay S. Tumor suppressor SMAR1 represses IkappaBalpha expression and inhibits p65 transactivation through matrix attachment regions. J Biol Chem 2009, 284:1267-1278.
132. Chew J., Biswas S., Shreeram S., Humaidi M., Wong E.T., Dhillion M.K., Teo H., Hazra A., Fang C.C., Lopez-Collazo E., Bulavin D.V., Tergaonkar V. WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat Cell Biol 2009, 11:659-666.
133. Chen L., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001, 293:1653-1657.
134. Tergaonkar V., Perkins N.D. p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol Cell 2007, 26:158-159.
135. Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J., Guru S.C., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J., Burns A.L. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001, 20:4917-4925.
136. Garkavtsev I., Kozin S.V., Chernova O., Xu L., Winkler F., Brown E., Barnett G.H., Jain R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428:328-332.
137. Liu B., Yang R., Wong K.A., Getman C., Stein N., Teitell M.A., Cheng G., Wu H., Shuai K. Negative regulation of NF-kappaB signaling by PIAS1. Mol Cell Biol 2005, 25:1113-1123.
138. Huang J.Y., Shen B.J., Tsai W.H., Lee S.C. Functional interaction between nuclear matrix-associated HBXAP and NF-kappaB. Exp Cell Res 2004, 298:133-143.
139. Biswas S.K., Tergaonkar V. Myeloid differentiation factor 88-independent toll-like receptor pathway: sustaining inflammation or promoting tolerance?. Int J Biochem Cell Biol 2007, 39:1582-1592.
140. Dey A., Tergaonkar V., Lane D.P. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 2008, 7:1031-1040.
141. Dey A., Wong E.T., Bist P., Tergaonkar V., Lane D.P. Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle 2007, 6:2178-2185.
142. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004, 13:853-865.
143. Campbell K.J., O'Shea J.M., Perkins N.D. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. BMC Cancer 2006, 6:101.
144. Ing N.H. Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. Biol Reprod 2005, 72:1290-1296.
145. Carlson B., Lahusen T., Singh S., Loaiza-Perez A., Worland P.J., Pestell R., Albanese C., Sausville E.A., Senderowicz A.M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999, 59:4634-4641.
146. Hsiang C.H., Straus D.S. Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. Oncogene 2002, 21:2212-2226.
147. Gorospe M., Liu Y., Xu Q., Chrest F.J., Holbrook N.J. Inhibition of G1 cyclin- dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol 1996, 16:762-770.
148. Lin S., Wang W., Wilson G.M., Yang X., Brewer G., Holbrook N.J., Gorospe M. Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol 2000, 20:7903-7913.
149. Pavithra L., Rampalli S., Sinha S., Sreenath K., Pestell R.G., Chattopadhyay S. Stabilization of SMAR1 mRNA by PGA2 involves a stem loop structure in the 5' UTR. Nucleic Acids Res 2007, 35:6004-6016.
150. Derrigo M., Cestelli A., Savettieri G., Di L. I, RNA-protein interactions in the control of stability and localization of messenger RNA (review). Int J Mol Med 2000, 5:111-123.
151. Smith L. Post-transcriptional regulation of gene expression by alternative 5'-untranslated regions in carcinogenesis. Biochem Soc Trans 2008, 36:708-711.
152. Pavithra L., Sreenath K., Singh S., Chattopadhyay S. Heat-shock protein 70 binds to a novel sequence in 5' UTR of tumor suppressor SMAR1 and regulates its mRNA stability upon Prostaglandin A2 treatment. FEBS Lett 2010, 584:1187-1192.
153. Brodsky J.L., Chiosis G. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr Top Med Chem 2006, 6:1215-1225.